The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
In just three weeks, the Hepatitis C drug in development, GS-7977, led to a sustained virologic response in over 90 percent of patients when paired with ribavirin and pegylated interferon.
Continue reading »Treatment naïve patients with Hepatitis C genotype 1 boasted a 100 percent success rate when given Gilead's GS-7977 and Bristol-Myers Squibb's daclatasvir.
Continue reading »Boehringer Ingelheim's all oral Hepatitis C drugs cured 82 percent of patients with the most common type of Hepatitis C in mid-stage trials. In addition, these drugs exhibited the potential to cure people with cirrhosis.
Continue reading »A combination of oral drugs - ribavirin and two of Abbott's drugs in development - demonstrated unprecedented Hepatitis C cure rates in a small, mid-stage study.
Continue reading »Using an approach called exhaustive panning, Scripps researchers have advanced the search for a Hepatitis C vaccine by identifying the antibody AR4A.
Continue reading »The individual who first identified the Hepatitis C virus might be the same person responsible for ending its infectious reign.
Continue reading »By delivering genetic material to initiate a T cell response, Okairos is looking to create the first Hepatitis C preventative vaccine.
Continue reading »In two separate Phase 3 trials, Hepatitis C patients with genotypes 1 and 4 are being treated with TMC435 plus pegylated interferon and ribavirin.
Continue reading »The leading medical research and advisory firm sets new gold standards of treatment for Hepatitis C non-responders in 2012 and 2015.
Continue reading »Combining two different medical traditions may provide the best relief for side effects originating from the latest Hepatitis C drugs.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
